112.47
前日終値:
$111.59
開ける:
$111.6
24時間の取引高:
7.52M
Relative Volume:
0.65
時価総額:
$194.62B
収益:
$46.59B
当期純損益:
$5.41B
株価収益率:
36.35
EPS:
3.0938
ネットキャッシュフロー:
$7.38B
1週間 パフォーマンス:
-3.58%
1か月 パフォーマンス:
+4.85%
6か月 パフォーマンス:
-3.33%
1年 パフォーマンス:
-14.39%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
112.47 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
330.69 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
91.23 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.84 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
90.21 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 開始されました | The Benchmark Company | Buy |
| 2025-07-18 | アップグレード | Jefferies | Hold → Buy |
| 2025-06-16 | 開始されました | Leerink Partners | Market Perform |
| 2024-10-08 | 開始されました | Oppenheimer | Outperform |
| 2024-09-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 繰り返されました | Barclays | Overweight |
| 2023-04-20 | 繰り返されました | Bernstein | Outperform |
| 2023-04-20 | 繰り返されました | JP Morgan | Overweight |
| 2023-04-20 | 繰り返されました | Raymond James | Outperform |
| 2023-04-20 | 繰り返されました | UBS | Buy |
| 2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2022-10-26 | 開始されました | Mizuho | Neutral |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-06 | 開始されました | Wolfe Research | Underperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | UBS | Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 開始されました | Redburn | Neutral |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Outperform |
| 2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
| 2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-11-30 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-16 | 開始されました | Barclays | Overweight |
| 2018-06-27 | 開始されました | Bernstein | Outperform |
| 2018-01-30 | 繰り返されました | Citigroup | Neutral |
| 2018-01-25 | 繰り返されました | Stifel | Buy |
| 2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Exact Sciences stock enters new chapter after Abbott acquisition - Ad-hoc-news.de
Abbott Agrees to $670 Million Settlement in Premature Infant Formula Litigation - finance.biggo.com
Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration - TipRanks
TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth - Investing.com
Abbott Laboratories settles multitude of infant formula legal claims - Yahoo Finance
Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation - Yahoo Finance
Abbott agreed to pay $670 million to settle preterm baby formula lawsuits - qz.com
Abbott Laboratories stock holds firm after Q2 beat - Ad-hoc-news.de
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Times West Virginian
True North Advisors LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Asset Advisors Investment Management LLC Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Exchange Traded Concepts LLC Has $6.85 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC - MarketBeat
Capital Investment Advisory Services LLC Sells 12,335 Shares of Abbott Laboratories $ABT - MarketBeat
ABN Amro Investment Solutions Purchases 19,480 Shares of Abbott Laboratories $ABT - MarketBeat
Alecta Tjanstepension Omsesidigt Acquires 153,500 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Inks $670M Deal To End Some Preterm Formula Claims - Law360
Abbott Will Pay $670 Million To End 2,000 Infant Formula Claims - NDTV Profit
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative? - simplywall.st
Abbott to pay $670 million to settle some preterm infant formula cases - The Lufkin Daily News
Abbott Reaches $670 Million Settlement in Infant Formula Litigation - Devdiscourse
Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge? - Yahoo Finance
Abbott Laboratories Reaches $670 Million Settlement in NEC Infant Formula Lawsuits - Kalkine Media
Abbott to Pay $670 Million to Settle Baby-Formula Litigation - WSJ
Abbott agrees to $670 million settlement of infant formula cases - The Lufkin Daily News
Abbott settles preterm formula litigation for $670 million By Investing.com - Investing.com Canada
Abbott's $670 Million Settlement Resolves Infant Formula Legal Claims - Devdiscourse
Abbott in $670M settlement for some NEC infant formula claims (ABT:NYSE) - Seeking Alpha
Abbott agrees to pay ~$670M to resolve Gill case and ~2,000 related preterm formula claims - TradingView
Abbott settles $670M lawsuits over preterm infa... - Pluang
Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims - Bloomberg.com
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants - PR Newswire
Abbott pays $670 million to settle 2,000 baby formula claims - Crain's Chicago Business
MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor - Yahoo! Finance Canada
Avricore and Abbott Labs sign UK pharmacy testing deal | 2026-08-20 | Investing News - Stockhouse
Mirae Asset Global Investments Co. Ltd. Raises Position in Abbott Laboratories $ABT - MarketBeat
Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT - MarketBeat
Citizens National Bank Trust Department Acquires 11,285 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? - Yahoo Finance
Abbott settles appeal of $495 million infant formula verdict - Investing.com
Richard W. Allen of Georgia’s 12th district makes significant trades in Abbott Laboratories and Advanced Micro Devices - Investing.com India
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch - simplywall.st
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability - simplywall.st
Abbott settles appeal over $495 million infant formula verdict - Reuters
Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices. - Pluang
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst - The Globe and Mail
Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade) - Seeking Alpha
The Smartest Dividend ETF to Buy With $500 Right Now - The Globe and Mail
5 questions on Abbott’s glucose-ketone sensors - MedTech Dive
Abbott Laboratories raises earnings outlook aft... - Pluang
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
Abbott Laboratories (ABT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
大文字化:
|
ボリューム (24 時間):